Literatur
- 1
Akbar A, Lord J M, Salmon M.
IFN-α and
IFN-β: a link between immune memory and chronic inflammation.
Immunol
Today.
2000;
21
337-342
- 2
Arnott I DR, Shand A, Ghosh S.
Administration
of Infliximab in Crohn’s disease does not deplete complement
components C3 an C4.
Am J Gastroenterol.
2000;
95
3320-3321
- 3
Beutler B, Krochin N, Milsark I W, Luedke C, Cerami A.
Control
of cachectin (tumour necrosis factor) protects mice from lethal
effect of endotoxin.
Science.
1986;
232
977-980
- 4
Bickston S J, Lichtenstein G R, Arseneau K O, Cohen R B, Cominelli F.
The
relationship between infliximab treatment and lymphoma in Crohn’s
disease.
Gastroenterology.
1999;
117
1433-1437
- 5
Brandtzaeg P, Farstad I N, Haraldsen G.
Regional
specialization in the mucosal immune system; primed cells do not
always home along the same track.
Immunol Today.
1999;
6
267-277
- 6
Braunstein J, Qiao L, Autschbach F, Schürmann G, Meuer S.
T
cells of the human intestinal lamina propria are high producers
of interleukin-10.
Gut.
1997;
41
215-220
- 7
Choy E H, Rankin E C, Kassimos D. et al .
The engineered human anti-tumor necrosis
factor-alpha antibody CDP571 inhibits inflammatory pathways but
not T cell activation in patients with rheumatoid arthritis.
J
Rheumatol.
1999;
26
2310-2317
- 8
Cohen R D, Tsang J F, Hanauer S B.
Infliximab
in Crohn’s disease: first anniversary clinical experience.
Am
J Gastroenterol.
2000;
95
3469-3477
- 9
D’Haens G, Swijsen C, Noman M, Lemmens L, Geboes K, Rutgeerts P.
Etanercept (TNF receptor
fusion protein, Enbrelš) is effective and well tolerated
in active refractory Crohn’s disease: Results of a single
center pilot trial.
Gastroenterology (Abs.).
2000;
118
3600
- 10
Desreumaux P, Brandt E, Bambiez L. et al .
Distinct cytokine pattern in early and
chronic ileal lesions of Crohn’s diease.
Gastroenterology.
1997;
113
118-126
- 11
Ehrenpreis E D, Kane S V, Cohen L B, Cohen R D, Hanauer S B.
Thalidomide
therapy for patients with refractory Crohn’s disease: an open-label
trial.
Gastroenterology.
1999;
117
1271-1277
- 12
Eigler A, Loher F, Endres S.
Suppression
der Synthese des Tumornekrosefaktor.
Der Internist.
2001;
42
28-34
- 13
Evans R C, Clarke L, Heath P, Stephens S, Morris A I, Rhodes J M.
Treatment
of ulcerative colitis with an engineered anti-TNFα antibody
CDP571.
Aliment Pharmacol Ther.
1997;
11
1031-1035
- 14
Farrell R J, Ang Y, Kileen P. et
al .
Increased incidence of non-Hodgkin’s lymphoma
in inflammatory bowel disease patients on immunosuppressive therapy
but overall risk is low.
Gut.
2000;
47
514-519
- 15
Farrell R J, Shah S A, Lodhavia P J. et al .
Clinical experience with infliximab therapy
in 100 patients with Crohn’s disease.
Am J Gastroenterol.
2000;
95
3490-3497
- 16
Fedorak R N, Gangl A, Elson C O. et al .
Recombinant human interleukin 10 in the
treatment of patients with mild to moderate active Crohn’s
disease.
Gastroenterology.
2000;
119
1473-1482
- 17
Fuss I J, Neurath N, Boirivant M. et al .
Disparate CD4+ lamina propria
lymphokine secretion profiles in inflammatory bowel disease. Crohn’s
disease LP cells manifest increased secretion of IFN-gamma, whereas
ulcerative colitis LP cells manifest increased secretion of IL-5.
J
Immunol.
1996;
157
1261-1270
- 18
Gasche C, Reinisch W, Vogelsang H. et al .
Prospective evaluation of interferon-alpha
in treatment of chronic active Crohn’s disease.
Dig
Dis Sci.
1995;
40
800-804
- 19
Geißler M, Blum H E.
Therapeutische
monoklonale Antikörper.
Dtsch Med Wschr.
2000;
125
1501-1504
- 20
Kempeni J.
Update
on D2E7: A fully human anti-tumour necrosis factor alpha monoclonal
antibody.
Ann Rheum Dis.
2000;
59
i44-i45
(suppl))
- 21
Kugathasan S, Werlin S L, Martinez A, Rivera M T, Heikenen J B, Binion D G.
Prolonged duration
of response to infliximab in early but not late pediatric Crohn’s
disease.
Am J Gastroenterol.
2000;
95
3189-3194
- 22
Lochs H, Adler G, Beglinger C. et al .
Anti-TNF
antibody in Crohn’s disease - status of information,
comments and recommendations of an international working group.
Z
Gastroenterol.
1999;
37
509-512
- 23
Maini R N, Elliott M, Brennan F M, Williams R O, Feldmann M.
Targeting
TNF alpha for the therapy of rheumatoid arthritis.
Clin
Exp Rheumatol.
1994;
12
S63-S66
(Suppl 1))
- 24
Marth T, Zeitz M.
Konventionelle
und immunmodulatorische Therapie bei chronisch-entzündlichen
Darmerkankungen.
Dtsch Med Wschr.
1999;
124
1173-1177
- 25
Menghini V V, Arora A S.
Infliximab-associated
reversible cholestatic liver disease.
Mayo Clin Proc.
2001;
76
84-86
- 26
Moreland L W, Baumgartner S W, Schiff M H. et al .
Treatment of rheumatoid arthritis with
a recombinant human tumor necrosis factor receptor (p-75)-Fc fusion
protein.
N Engl J Med.
1997;
340
1398-1405
- 27
Neurath M, Fuss I, Kelsall B L, Stüber E, Strober W.
Antibodies
to interleukin 12 abrogate established experimental colitis in mice.
J Exp
Med.
1995;
182
1281-1290
- 28
Nicolaus S, Raedler A, Kuhbacker T, Sfikas N, Fölsch U R, Schreiber S.
Mechanisms in failure
of infliximab for Crohn’s disease.
Lancet.
2000;
356
1475-1479
- 29
Poltorak A, Peppel K, Beutler B.
Receptor-mediated
label-transfer assay (RELAY) - a novel method for the detection
of plasma tumor necrosis factor at attomolar concentrations.
J
Immunol Methods.
1994;
169
93-99
- 30
Present D H, Rutgeerts P, Targan S. et al .
Infliximab for the treatment of fistulas
in patients with Crohn’s disease.
N Engl J Med.
1999;
340
1398-1405
- 31
Qiao L, Braunstein J, Golling M. et al .
Differential
regulation of human T cell responsiveness by mucosal versus blood
monocytes.
Eur J Immunol.
1996;
26
922-927
- 32
Qiu B S, Pfeiffer C J, Keith J CJ.
Protection
of recombinant human interleukin-11 against experimental TNB-induced
colitis in rats.
Dig Dis Sci.
1996;
41
1625-1630
- 33
Ricart E, Pannaccione R, Loftus E V, Tremaine W J, Sandborn W J.
Successful
management of Crohn’s disease of the ileoanal pouch with
infliximab.
Gastroenterology.
1999;
117
429-432
- 34
Rogler G, Brand K, Vogl D. et
al .
Nuclear factor kappa B is activated in macrophages
and epithelial cells of inflamed intestinal mucosa.
Gastroenterology.
1998;
115
357-369
- 35
Rutgeerts P, D’Haens G, Targan S. et al .
Efficacy and safety of retreatment with
anti-tumor necrosis factor antibody (Infliximab) to maintain remission
in Crohn’s disease.
Gastroenterology.
1999;
117
761-769
- 36
Sandborn W J, Hanauer S B.
Antitumor
necrosis factor therapy for inflammatory bowel disease: A review
of agents, pharmacology, clinical results, and safety.
Inflamm
Bowel Dis.
1999;
5
119-133
- 37
Sands B E.
Therapy
of inflammatory bowel disease.
Gastroenterology.
2000;
118
S68-S82
(Suppl)
- 38
Sands B E, Bank S A, Sninsky C A. et al .
Preliminary evaluation of safety and activity
of recombinant human interleukin 11 in patients with active Crohn’s
disease.
Gastroenterology.
1999;
117
58-64
- 39
Sands B E, Podolsky D K, Tremaine W J. et al .
Chimeric monoclonal anti-tumor necrosis
factor alpha antibody (cA2) in the treatment of severe, steroid-refractory
ulcerative colitis.
Gastroenterology.
1996;
110
A1008
- 40
Schieferdecker H L, Ullrich R, Hirseland H, Zeitz M.
T cell differentiation
antigens on lymphocytes in human intestinal lamina propria.
J
Immunol.
1992;
149
2816-2822
- 41
Schölmerich J.
Which
immunosuppressors do you use to treat Crohn’s diseae and
ulcerative colitis? In which order of priority and how worried are
you about toxicity?.
Inflamm Bowel Dis.
1998;
4
248-252
- 42
Schreiber S, Fedorak R N, Nielson O H. et al .
Safety and efficacy of recombinant human
interleukin-10 chronic active Crohn’s disease.
Gastroenterology.
2000;
119
1461-1472
- 43
Schreiber S, Fedorak R N, Wild G. et al .
Safety and tolerance of rHuIL-10 treatment
in patients with mild/moderate active ulcerative colitis.
Gastroenterology.
1998;
114
A1079
- 44
Sheldon D G, Sawchuk L L, Kozarek R A, Thirlby R C.
Twenty cases
of peristomal pyoderma gangrenosum.
Arch Surg.
2000;
135
564-569
- 45
Soykan I, Ertan C, Özden A.
Severe
anaphylactic reaction to infliximab: Report of a case.
Am
J Gastroenterol.
2000;
95
2395-2396
- 46
Stack W A, Mann S D, Roy A J. et al .
Randomised controlled trial of CDP571 antibody
to tumour necrosis factor-alpha in Crohn’s disease.
Lancet.
1997;
349
521-524
- 47
Strober W, Fuss I J, Erhardt R O, Neurath M, Boirivant M, Ludviksson B R.
Mucosal
immune regulation and inflammatory bowel disease: new insights from
murine models of inflammation.
Scand J Immunol.
1998;
48
453-458
- 48 Strober W, Neurath M F. Immunological
diseases of the gastrointestinal tract. l. St.
Louis: Mosby In: Rich, R. R., Ed. Book 1995: 1401-1428
- 49
Sümer N, Palabiyikoglu M.
Induction of remission
by interferon-alpha in patients with chronic active ulcerative colitis.
Eur
J Gastroenterol Hepatol.
1995;
7
597-602
- 50
Targan S R, Hanauer S B, van Deventer S JH. et al .
A short-term study of chimeric monoclonal
antibody cA2 to tumor necrosis factor alpha for Crohn’s
disease. Crohn’s Disease cA2 Study Group.
N Engl
J Med.
1997;
337
1029-1035
- 51
van Deventer S JH, Elson C O, Fedorak R N.
Multiple
doses of intravenous interleukin 10 in steroid-refractory Crohn’s
disease. Crohn’s Disease Study Group.
Gastroenterology.
1997;
113
383-389
- 52
van Dullemen H M, van Deventer S JH, Hommes D W. et al .
Treatment of Crohn’s disease with
anti-tumor necrosis factor chimeric monoclonal antibody (cA2).
Gastroenterology.
1995;
109
129-135
- 53
Vantrappen G, Coremans G, Billiau A, De Somer P.
Treatment of Crohn’s
disease with interferon. A preliminary clinical trial.
Acta Clin
Belg.
1980;
35
238-242
- 54
Vasiliauskas E A, Kam Y L, Abreu-Martin M T. et al .
An open-label pilot study of low-dose thaliomide
in chronically active, steroid-dependent Crohn’s disease.
Gastroenterology.
1999;
117
1278-1287
- 55
Vermeire S, Monsuur F, Groenen P, Peeters M, Vlietinck R, Rutgeerts P.
Response to anti-TNFα-treatment
is associated with the TNF-308.1 allele.
Gastroenterology.
2000;
118
3595
- 56
Zeitz M.
Pathogenesis
of inflammatory bowel disease.
Digestion.
1997;
58
59-61
(Suppl 1))
- 57
Zeitz M, Schieferdecker H L, Ullrich R, Jahn H U, James S P, Riecken E O.
Phenotype
and function of lamina propria T cells.
Immunol Res.
1991;
10
199-206
Korrespondenz
Prof. Dr. M. Zeitz
Direktor der Medizinische Klinik I (Gastroenterologie,
Infektiologie, Rheumatologie)
Universitätsklinikum
Benjamin Franklin Freie Universität Berlin
Hindenburgdamm 30
12200 Berlin
Telefon: 030/8445-2347
Telefon: 030/8445-4481
eMail: zeitz@ukbf.fu-berlin.de
